NVO Stock Today (Nov 6, 2025): Novo Nordisk volatile as White House pricing deal reshapes GLP‑1 market—what it means for Wegovy, Ozempic and investors
Published: November 6, 2025 TL;DR: Novo Nordisk’s U.S.‑listed shares (NYSE: NVO) swung after the White House announced a pricing-and-access deal with Novo and Eli Lilly that expands Medicare coverage for anti‑obesity drugs and cuts out‑of‑pocket costs. As of 17:51 UTC (12:51 p.m. ET), NVO traded around $47.30, down ~2.4% on the day (intraday range: $46.91–$49.49; volume ~29.3M). The company confirmed a Medicare Part D pilot beginning in 2026, lower U.S. prices in Medicare/Medicaid and cash channels, and a three‑year tariff exemption—and flagged a low single‑digit drag to 2026 global sales growth. GlobeNewswire What’s moving NVO today White House deal cuts